Total Funding
92
55
Total FundingSeed raised
Growth Score
12 pts
Heat Score
50 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
60395
Evolyra Therapeutics develops next-generation AAV gene therapies for limb-girdle muscular dystrophy and other rare neuromuscular diseases.
About the Company
Evolyra Therapeutics develops gene replacement therapies for rare neuromuscular diseases, with an initial focus on limb-girdle muscular dystrophy (LGMD) types 2C and 2D. The company designs second-generation AAV vectors that deliver full-length functional genes to skeletal muscle while reducing liver toxicity. Its approach emphasizes one-time
infusion treatments and a scalable, modular platform to address 20+ LGMD subtypes. Evolyra collaborates with academic centers and the GRASP-LGMD Patient Consortium and advances preclinical, manufacturing, and regulatory programs toward future clinical trials.
